神经退行性变
神经病理学
神经炎症
氧化应激
神经科学
普鲁士蓝
阿尔茨海默病
纳米囊
医学
药理学
化学
疾病
心理学
病理
内科学
材料科学
纳米技术
物理化学
纳米颗粒
电化学
电极
作者
Xiaojun Cai,Kai Zhang,Xue Xie,Xifang Zhu,Jundong Feng,Zhiming Jin,Hong Zhang,Mei Tian,Hangrong Chen
出处
期刊:Biomaterials
[Elsevier]
日期:2020-02-01
卷期号:231: 119678-119678
被引量:35
标识
DOI:10.1016/j.biomaterials.2019.119678
摘要
Alzheimer's disease (AD) is a prevalent chronic neurodegenerative disease. However, to date, none of the developed drug candidates targeting at a single therapeutic target of AD have achieved success in clinical trials. Herein, we proposed a hypothesis of hollow manganese Prussian white nanocapsules (HMPWCs)-mediated attenuation of Tau-related pathology and alleviation of cognitive decline via simultaneously alleviating neuroinflammation, scavenging reactive oxygen species, and reducing hyperphosphorylated Tau proteins. The HMPWCs self-assemblied with manganese Prussian white analogue and bovine serum albumin via a novel biomimetic mineralization present good biocompatibility, variable valence states, and low oxidation-reduction potential. They own the outstanding capabilities of relieving oxidative stress, inhibiting Tau neuropathology, and counteracting neuroinflammation, which could be used to treat Tau-related AD-like neurodegeneration. Importantly, they can also attenuate the cognitive impairments of Tau-related AD-like rats without significant side effects. This research takes the advantages of catalytic chemistry, nanomedicine and specific neurodegenerative microenvironment together, providing an alternative efficient treatment strategy for Tau-related neurodegeneration diseases, such as AD, Pick's disease, frontotemporal dementia, Creutzfeldt-Jakob Disease and progressive supranuclear palsy.
科研通智能强力驱动
Strongly Powered by AbleSci AI